Jonathan PoyerFeb 23, 20232 min readDrug Approvals for Travere and Apellis - But Did Biotech Overall Budge?
Jonathan PoyerFeb 14, 20231 min readBiotech & HealthcareBe Careful What You Own in Biotech - Wheat and Chaff Abounds
Jonathan PoyerFeb 13, 20232 min readBiotech & HealthcareHunting for Deals? Biotech and Pharma On the Move
Jonathan PoyerFeb 9, 20232 min readBiotech & HealthcareBiotech and Soft Landings: Will Bears Drive Valuations Down?
Jonathan PoyerFeb 6, 20232 min readMacro ViewsCan the Bond Market Get Any Worse? Why There is Optimism for 2023
Jonathan PoyerFeb 6, 20231 min readBiotech & HealthcareOverview of Biotech Capital Markets and Activity Through Week Ended January 27th
Jonathan PoyerFeb 6, 20231 min readBiotech & HealthcareLet's Peek at Biotech Performance: What to Expect After Back-to-Back Down Years?
Jonathan PoyerFeb 1, 20231 min readBiotech & HealthcarePick The Winners but Avoid the Losers in Biotech
Jonathan PoyerJan 30, 20232 min readMacro ViewsWill RMBS Securities Benefit from A Strong Housing Market? Is Housing Strong?
Jonathan PoyerJan 30, 20231 min readMunicipal BondsAre The Markets Itching to Sell Equities and Buy Bonds?
Jonathan PoyerJan 26, 20232 min readReal EstateMortgage REITs in 2022 - Not Immune to Weakness but Primed for Strength